AcelRx Pharma (ACRX) Says ARX-04 Phase 3 Met Primary Endpoint in Trauma/Injury Pain Reduction
Go back to AcelRx Pharma (ACRX) Says ARX-04 Phase 3 Met Primary Endpoint in Trauma/Injury Pain Reduction| ACELRX PHARMA (NASDAQ: ACRX) | Delayed: 0.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.86 | 52 Week High | $5.88 | |||
| Open | $0.86 | 52 Week Low | $2.40 | |||
| Day High | $0.86 | P/E | N/A | |||
| Day Low | $0.86 | EPS | $-1.50 | |||
| Volume | 1,425 | |||||
